Tags

Type your tag names separated by a space and hit enter

Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome.
Rev Gastroenterol Disord. 2009 Winter; 9(1):7-15.RG

Abstract

Irritable bowel syndrome (IBS) is a common disorder with widespread prevalence. Due to its heterogeneous pathogenesis, efficacious treatments are lacking. The few medications that are effective for treating global IBS symptoms have either been withdrawn or restricted due to detrimental side effects; thus, safe and effective alternatives are urgently needed. Increasing data have revealed that inflammatory changes may play a role in the development of IBS, and probiotics, commensal organisms with inherent health benefits, may alter that milieu. Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are strain specific. Bifidobacterium infantis 35624 (B infantis 35624; Bifantis, The Procter & Gamble Company, Cincinnati, OH), is a probiotic with unique abilities to reduce intestinal inflammation. Two randomized, controlled trials have validated its efficacy for treating both individual and global IBS symptoms without evidence to suggest an increase in adverse events. B. infantis 35624 appears safe and effective for the treatment of IBS.

Authors+Show Affiliations

Division of Gastroenterology, Department of Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19367213

Citation

Brenner, Darren M., and William D. Chey. "Bifidobacterium Infantis 35624: a Novel Probiotic for the Treatment of Irritable Bowel Syndrome." Reviews in Gastroenterological Disorders, vol. 9, no. 1, 2009, pp. 7-15.
Brenner DM, Chey WD. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord. 2009;9(1):7-15.
Brenner, D. M., & Chey, W. D. (2009). Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Reviews in Gastroenterological Disorders, 9(1), 7-15.
Brenner DM, Chey WD. Bifidobacterium Infantis 35624: a Novel Probiotic for the Treatment of Irritable Bowel Syndrome. Rev Gastroenterol Disord. 2009;9(1):7-15. PubMed PMID: 19367213.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. AU - Brenner,Darren M, AU - Chey,William D, PY - 2009/4/16/entrez PY - 2009/4/16/pubmed PY - 2009/6/19/medline SP - 7 EP - 15 JF - Reviews in gastroenterological disorders JO - Rev Gastroenterol Disord VL - 9 IS - 1 N2 - Irritable bowel syndrome (IBS) is a common disorder with widespread prevalence. Due to its heterogeneous pathogenesis, efficacious treatments are lacking. The few medications that are effective for treating global IBS symptoms have either been withdrawn or restricted due to detrimental side effects; thus, safe and effective alternatives are urgently needed. Increasing data have revealed that inflammatory changes may play a role in the development of IBS, and probiotics, commensal organisms with inherent health benefits, may alter that milieu. Although their exact mechanisms of action remain elusive, it is clear that the beneficial properties inherent to each probiotic species are strain specific. Bifidobacterium infantis 35624 (B infantis 35624; Bifantis, The Procter & Gamble Company, Cincinnati, OH), is a probiotic with unique abilities to reduce intestinal inflammation. Two randomized, controlled trials have validated its efficacy for treating both individual and global IBS symptoms without evidence to suggest an increase in adverse events. B. infantis 35624 appears safe and effective for the treatment of IBS. SN - 1533-001X UR - https://www.unboundmedicine.com/medline/citation/19367213/Bifidobacterium_infantis_35624:_a_novel_probiotic_for_the_treatment_of_irritable_bowel_syndrome_ L2 - http://www.diseaseinfosearch.org/result/3876 DB - PRIME DP - Unbound Medicine ER -